MyFinsight
Home
Blog
About
Jazz Pharmaceuticals plc (JAZZ)
Jazz Pharmaceuticals plc (JAZZ)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$224,500K
Free Cash flow
$397,600K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from maturity of invest...
Net income (loss)
Intangible asset amortization
Others
Negative Cash Flow Breakdown
Repayment of 2026 notes
Acquisition of investments
Acquired in-process research and...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net income (loss)
192,800
293,100
203,451
251,412
Intangible asset amortization
170,000
172,300
169,742
168,368
Share-based compensation
73,300
74,500
70,854
88,125
Acquired in-process research and development
77,000
-
0
42,500
Acquisition accounting inventory fair value step-up adjustment
16,600
37,500
40,604
40,355
Provision for losses on accounts receivable and inventory
7,500
14,200
4,114
8,223
Depreciation
9,100
9,100
9,427
9,878
Non-cash interest expense
4,900
4,700
5,329
5,299
Deferred tax benefit
-38,700
-66,200
-63,309
-271,410
Impairment of property, plant and equipment
-
-
0
-
Gain on sale of priority review voucher
0
122,800
-
-
Other non-cash transactions
2,400
-3,900
4,955
-1,016
Accounts receivable
44,900
6,500
65,813
50,996
Inventories
29,900
77,800
-7,720
31,909
Prepaid expenses and other assets
-4,900
-51,900
-27,492
6,674
Operating lease assets
-
-
-
-3,178
Other non-current assets
-
-
-
-18,824
Accounts payable
28,500
-21,400
-28,972
62,358
Accrued liabilities
8,500
-7,900
26,170
126,277
Income taxes payable
-37,700
37,400
-34,784
12,738
Operating lease liabilities, less current portion
-
-
-
-3,475
Other non-current liabilities
-
-
-
529
Other liabilities
-23,800
12,200
28,018
-
Net cash provided by operating activities
415,700
408,200
362,518
474,616
Proceeds from maturity of investments
720,000
520,000
180,000
400,000
Proceeds from sale of priority review voucher
0
200,000
28,167
-
Payments related to sale of priority review voucher
0
77,200
-
-
Purchases of property, plant and equipment
18,100
19,700
16,729
15,175
Acquired in-process research and development
77,000
-
0
42,500
Acquisition of investments
270,000
500,000
510,100
640,125
Acquisition of intangible assets
0
0
53,500
30,000
Asset acquisition, net of cash acquired
0
-
0
0
Net cash provided by (used in) investing activities
354,900
123,100
-372,162
-327,800
Repayment of 2026 notes
1,000,000
-
0
0
Payment of employee withholding taxes related to share-based awards
9,500
103,600
1,996
3,812
Repayments of long-term debt
7,700
7,800
7,750
7,750
Payment of debt modification costs
-
-
0
-
Proceeds from employee equity incentive and purchase plans
22,700
32,900
85,186
733
Net proceeds from issuance of 2030 notes
-
-
0
0
Share repurchases
0
-
0
0
Net cash used in financing activities
-994,500
-78,500
75,440
-10,829
Effect of exchange rates on cash and cash equivalents
-600
-400
33
203
Net increase (decrease) in cash and cash equivalents
-224,500
452,400
65,829
136,190
Cash and cash equivalents, at beginning of period
1,844,300
1,391,900
1,326,070
2,412,864
Cash and cash equivalents, at end of period
1,619,800
1,844,300
1,391,899
1,326,070
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net income (loss)
$192,800K
(123.77%↑ Y/Y)
Intangible asset
amortization
$170,000K
(-46.30%↓ Y/Y)
Acquired in-process
research and development
$77,000K
(-91.50%↓ Y/Y)
Proceeds from maturity of
investments
$720,000K
(-7.69%↓ Y/Y)
Share-based compensation
$73,300K
(-44.53%↓ Y/Y)
Accounts payable
$28,500K
(340.84%↑ Y/Y)
Acquisition accounting
inventory fair value...
$16,600K
(-75.22%↓ Y/Y)
Depreciation
$9,100K
(-59.25%↓ Y/Y)
Accrued liabilities
$8,500K
(111.28%↑ Y/Y)
Provision for losses on
accounts receivable and...
$7,500K
(10.77%↑ Y/Y)
Prepaid expenses and
other assets
-$4,900K
(40.33%↑ Y/Y)
Non-cash interest
expense
$4,900K
(-77.64%↓ Y/Y)
Net cash provided by
operating activities
$415,700K
(-19.85%↓ Y/Y)
Net cash provided by
(used in) investing...
$354,900K
(143.82%↑ Y/Y)
Canceled cashflow
$177,400K
Canceled cashflow
$365,100K
Net increase
(decrease) in cash and cash...
-$224,500K
(81.64%↑ Y/Y)
Canceled cashflow
$770,600K
Proceeds from employee
equity incentive and...
$22,700K
(3.45%↑ Y/Y)
Accounts receivable
$44,900K
(526.40%↑ Y/Y)
Deferred tax benefit
-$38,700K
(64.90%↑ Y/Y)
Income taxes payable
-$37,700K
(-163.61%↓ Y/Y)
Inventories
$29,900K
(-51.66%↓ Y/Y)
Other liabilities
-$23,800K
Other non-cash
transactions
$2,400K
(134.08%↑ Y/Y)
Acquisition of investments
$270,000K
(-60.30%↓ Y/Y)
Acquired in-process
research and development
$77,000K
Purchases of property,
plant and equipment
$18,100K
(-32.58%↓ Y/Y)
Net cash used in
financing activities
-$994,500K
(-6.02%↓ Y/Y)
Canceled cashflow
$22,700K
Effect of exchange
rates on cash and cash...
-$600K
(-109.50%↓ Y/Y)
Repayment of 2026 notes
$1,000,000K
Payment of employee
withholding taxes related to...
$9,500K
(-86.31%↓ Y/Y)
Repayments of long-term
debt
$7,700K
(-98.99%↓ Y/Y)
Buy us a coffee